Piper Jaffray Companies Reiterates Hold Rating for Endo International PLC (ENDP)
Endo International PLC (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “hold” rating restated by equities research analysts at Piper Jaffray Companies in a report released on Friday. They presently have a $7.00 target price on the stock. Piper Jaffray Companies’ target price indicates a potential upside of 1.01% from the stock’s previous close.
A number of other research analysts have also recently commented on the company. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. ValuEngine cut Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research note on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 price target on Endo International PLC and gave the company a “hold” rating in a research note on Tuesday, October 17th. Finally, BidaskClub upgraded Endo International PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company’s stock. Endo International PLC presently has an average rating of “Hold” and an average target price of $11.67.
Endo International PLC (NASDAQ:ENDP) opened at $6.93 on Friday. Endo International PLC has a 12 month low of $5.77 and a 12 month high of $18.63. The company has a market capitalization of $1,359.98, a price-to-earnings ratio of 1.26 and a beta of 0.53. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 10.20.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. Endo International PLC had a positive return on equity of 56.97% and a negative net margin of 126.97%. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same period in the prior year, the company earned $1.01 EPS. Endo International PLC’s revenue was down 11.0% compared to the same quarter last year. sell-side analysts predict that Endo International PLC will post 3.54 earnings per share for the current fiscal year.
In other Endo International PLC news, CEO Paul Campanelli purchased 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average price of $7.71 per share, with a total value of $50,115.00. Following the transaction, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 16,000 shares of company stock worth $125,460. 0.50% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC lifted its position in Endo International PLC by 1.9% in the 2nd quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after acquiring an additional 15,928 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its position in Endo International PLC by 46.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after acquiring an additional 228,426 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Endo International PLC by 1.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after acquiring an additional 10,387 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Endo International PLC by 4.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock valued at $6,497,000 after acquiring an additional 27,414 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in Endo International PLC by 93.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock valued at $6,314,000 after acquiring an additional 273,024 shares in the last quarter. 90.32% of the stock is currently owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.